Risks to the 340B Drug Pricing Program / Reply

Knox and Sarpatwari respond to comments from Daifotis on their article regarding the risks to the 340B drug pricing program. Pharmaceutical manufacturers have unilaterally adopted a range of policies concerning the delivery of 340B discounted drugs to contract pharmacies, from requiring that certain covered entities submit insurance claims data for 340B drugs dispensed at these locations to limiting the number of contract pharmacies a covered entity can engage. They believe that it is accurate to label the former policy, which imposes a limiting condition, as a restriction.